Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|May 31, 2025
The orexin 1-selective receptor antagonist nivasorexant is a time-dependent inhibitor of CYP2C19 and CYP3A4Alexander Treiber, Fabienne Drouet, Swen Seeland, et al.
Bioorganic & Medicinal Chemistry Letters|October 11, 2008
N-Glycine-sulfonamides as potent dual orexin 1/orexin 2 receptor antagonistsHamed Aissaoui, Ralf Koberstein, Cornelia Zumbrunn, et al.
The AAPS Journal|December 23, 2011
Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonistShirin Bruderer, Päivi Aänismaa, Marie-Claude Homery, et al.
RSC Medicinal Chemistry|January 29, 2024
Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure-activity-relationship, and sleep-promoting properties in ratsChristine Brotschi, Martin H Bolli, John Gatfield, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 23, 2013
Elucidation of the metabolic pathways and the resulting multiple metabolites of almorexant, a dual orexin receptor antagonist, in humansJasper Dingemanse, Petra Hoever, Matthias Hoch, et al.
Clinical Pharmacokinetics|September 20, 2015
Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug InteractionsRuben de Kanter, Patricia N Sidharta, Stéphane Delahaye, et al.
Chemmedchem|March 9, 2023
CYP3A4 Catalyzes the Rearrangement of the Dual Orexin Receptor Antagonist Daridorexant to 4-Hydroxypiperidinol MetabolitesAlexander Treiber, Hamed Aissaoui, Stéphane Delahaye, et al.
Journal of Medicinal Chemistry|February 8, 2024
Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical TrialsJodi T Williams, Martin H Bolli, Christine Brotschi, et al.
Pharmacology Research & Perspectives|June 4, 2015
ATP-induced cellular stress and mitochondrial toxicity in cells expressing purinergic P2X7 receptorSwen Seeland, Hélène Kettiger, Mark Murphy, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|July 25, 2017
The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipagCarmela Gnerre, Jérôme Segrestaa, Swen Seeland, et al.
Pageof 5